Tagged with

Datapharm Australia Pty Ltd The Australian pharmaceutical sector has seen recent innovations through PBS reform and various working groups shaping the future of the industry. Can you comment on how Datapharm is reacting to these opportunities? Datapharm has actually put in a submission to the review of the National Innovation System, highlighting that innovation…

Genzyme Australia What impact will the recent PBS reforms have on Genzyme’s operations in Australia? Genzyme is different in terms of its focus on rare & unmet medical needs, so most of the company’s products, given they are targeted therapies, are not reimbursed through the PBS, but through other government funding mechanisms.…

Department of Health And Ageing New Government health priorities and policies, highlighting those concerning preventive health. The Rudd Labor Government’s goal in health is to create a modern health system designed for the health needs of the 21st century, including the growing burden of chronic disease. Bringing a greater focus to prevention in health policy…

Medicines Australia To begin, would you please introduce Medicines Australia to Pharmaceutical Executive readers? Medicines Australia is the national industry association for innovative pharmaceutical companies. . Just about every company engaged in the research and discovery of new medicines in Australia is a member of the association, so we have the capacity…

Pharmacor Pharmacor is one of the newest entities on the Australian pharmaceutical market. Would you please introduce the company to let Pharmaceutical Executive readers understand more about the Pharmacor story? Pharmacare Laboratories established Pharmacor approximately one year ago, and decided to divest the company two months ago, realizing that they preferred…

Nycomed Australia What impact have the PBS reforms had on Nycomed? As most mid size Pharma companies that operate in a setting of mass market prescription medicines, Nycomed is also experiencing the real impact of the PBS measures that have been implemented in recent years. The PBS reforms introduced in 2007 are…

Lloyd Sansom Would you please introduce the PBAC and the role it plays in Australia’s pharmaceutical sector? The Pharmaceutical Benefits Advisory Committee (PBAC) is a statutory committee of the Australian government which was first established in the 1940s, and which makes recommendations to the Minister of Health and Ageing regarding medicines which…

IMS Health Australia How have your experiences at Quintiles, Astra, Baxter, and Innovex – covering the spectrum from small to large pharma in addition to the service side – helped in managing IMS since your arrival in December 2007? Having been a client gives insights into the client side, and perspective on what…

Australian Self Medication Industry(ASMI) Molteni was created in 1892 and progressively developed a strong manufacturing base, a very active R&D department and a growing international presence. Could you introduce the story behind such achievements? The company was founded over a century ago by Leone Molteni in the backyard of Farmacia Molteni located in the…

Medicines Australia To begin, would you please introduce Medicines Australia to Pharmaceutical Executive readers? Medicines Australia is the association that represents the country’s research-based pharmaceutical industry. With approximately 50 members, the organization comprises all major innovator companies, consisting of the significant American and European pharmaceutical players, in addition to some Australian companies…

SERVIER Laboratories (Australia) Pty Ltd Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why Servier has invested more in Australia of late. What drives Servier’s headquarters to conduct more research in Australia is a…

Solvay Australia How will the PBS reforms affect Solvay? The easy answer is: heavily. Fortunately, Solvay’s leading product which is still under patent will not be subject to the full August 1 price cut at this stage. Nevertheless, there are two other drugs fully affected by the cut (-25%). This of course…